- Medicine - Nov 21 MVLS academics named as Highly Cited Researchers
- Medicine - Nov 21 Four Queen Mary University of London scientists make Highly Cited Researchers 2014 List
- Life Sciences - Nov 21 Report highlights opportunities and risks associated with synthetic biology and bioengineering
- Administration - Nov 21 Worldwide campaign on abortion raises $300m, UCL Lancet lecture told
- Medicine - Nov 20 Systems of change behind everything from climate to health
- Medicine - Nov 20 Young people have more varied sex lives than their parents
- Medicine - Nov 17 Foodbank users report benefit delays, adverse life events
- Physics - Nov 17 Controlling growth of organic crystals with high- powered magnets could have major benefits for pharmaceutical development
- Medicine - Nov 17 UofG signs historic agreement with Thailand’s Mahidol University
- Life Sciences - Nov 17 Puppy poo needed to monitor antibiotic- resistant bacteria
- Medicine - Nov 16 From Hong Kong high- rise to world- leading renal researcher
- Medicine - Nov 16 New talking therapy could help cancer survivors cope after treatment
Liverpool spin-out gets further funding boost for bedside sepsis test
A University of Liverpool spin-out company, Sepsis Limited has secured further funding support to test a point of care diagnostic tool for the early detection of sepsis.
The Small Business Research Initiative for Healthcare ( SBRI Healthcare ), led by the Academic Health Science Networks ( AHSNs ), has awarded the company £100,000 for the first phase of testing a working prototype of a hand held device that will be used at the patient bedside for rapid diagnosis and treatment of sepsis.
The award is part of an NHS England initiative aimed at helping healthcare organisations to improve their flow of patients.
Often referred to as blood poisoning, sepsis is the major cause of death worldwide. In the UK, approximately 100,000 people are admitted to hospital with sepsis and around 37,000 people will die as a result of the condition.
Sepsis Limited, which was spun out in 2010, is founded on the ground breaking research of blood specialist Professor Cheng-Hock Toh from the University’s Institute of Infection and Global Health.
The company’s hand-held device can detect abnormal blood chemistry due to bacterial sepsis within minutes of sampling and before standard physiological sepsis is diagnosed. It has been designed to frequently monitor progression of symptoms with a view to improve and measure the appropriate use of antibiotics and collectively meet objectives of the Department of Health’s UK Five Year Antimicrobial Resistance Strategy 2013-2018 .
Professor Toh, who also provides direct patient care at the Royal Liverpool University Hospital, said: ‘This new funding is an important step in helping us to translate our research into a bedside test that can quickly diagnose life-threatening sepsis, improve antibiotic usage, and ultimately save lives.’
Last job offers
- Medicine/Pharmacology - 17.11
Nuffield Professorship of Clinical Medicine
- Medicine/Pharmacology - 14.11
Chair in Healthcare Management
- Medicine/Pharmacology - 8.11
Lecturer (Assistant Professor) / Senior Lecturer (Associate Professor)
- Medicine/Pharmacology - 7.11
Associate Professor in Pharmacy Practice
- Medicine/Pharmacology - 6.11
Professor and Honorary Consultant in Anaesthesia and Perioperative Medicine
- Medicine/Pharmacology - 2.11
Associate Professor of Nursing
- Medicine/Pharmacology - 2.11
Associate Professor of Midwifery
- Medicine/Pharmacology - 27.10
Professor and Director, UCL Institute for Women’s Health